- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
1. Financial Highlights:
Dr. Reddy’s reported record consolidated revenue of ₹32,554 Cr in FY25, up 17% YoY, with EBITDA reaching ₹9,213 Cr at a 28% margin, growing 11%. PAT increased 17% to ₹5,654 Cr. Q4 revenues hit an all-time high of ₹8,506 Cr (+20% YoY) with EBITDA at ₹2,475 Cr (29% margin). RoCE stood strong at 28%, supported by a net cash surplus of ₹2,454 Cr. Revenue growth excluding the acquired Nicotine Replacement Therapy (NRT) business was a healthy 12% YoY, reflecting solid organic momentum.
2. Strategic Initiatives & Growth Drivers:
The company focused on scaling core generics worldwide through new launches and geographic expansion. The NRT business integration in the UK is complete, with plans for Nordic markets. R&D investments continue, with notable USFDA filing for denosumab biosimilar and partnerships to commercialize biosimilars across the US, Europe, and Southeast Asia. Collaboration with Sanofi to expand novel drug segment presence via Beyfortus® in India also progressed. Capex and innovation spends remain steady to support commercial and R&D capabilities.
3. Business Developments:
Dr. Reddy’s secured exclusive rights for daratumumab biosimilar (Henlius) and biosimilars ustekinumab and golimumab (Bio-Thera). It launched Sensimune™ for dust mite allergies in India and remains engaged with the Jan Aushadhi Program. The Shreveport manufacturing site in the US was divested to streamline assets.
4. Market Position & Competitive Advantage:
Strong geographic diversity with North America contributing 42% to Q4 revenue; India, Europe, and Emerging Markets recorded double-digit growth. The broad portfolio, especially in biosimilars and consumer healthcare, supports market share gains including 17 Indian brands crossing ₹100 Cr in sales. Leadership in stomatologicals and vaccines along with robust partnerships and pipeline strength underlines its edge in differentiated generics and biosimilars.
5. Investor Implications:
Robust financials, sustained double-digit revenue growth, and strategic biosimilar and consumer health investments indicate positive growth potential. Successful integration and pipeline execution are key strengths. Investors should monitor risks from price erosion in mature markets and regulatory outcomes. Overall, Dr. Reddy’s appears well positioned for medium-term value creation.